Survival of the fittest: Positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Kimpel, Janine ^a   Braun, Stephen E ^b   Qiu, Gang ^b   Wong, Fay Eng ^b   Conolle, Michelle ^b   Schmitz, Jörn E ^c   Brendel, Christian ^a   Humeau, Laurent M ^d   Dropulic, Boro ^d,i   Rossi, John J ^e   Berger, Annemarie ^f   von Laer, Dorothee ^a,g   Johnson, R Paul ^b,h  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d VIRxSYS Corporation   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ Lentigen Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COMPLEMENTARY RNA; HYBRID PROTEIN; LENTIVIRUS VECTOR; MEMBRANE ANCHORED C46 PEPTIDE; PEPTIDE; REV PROTEIN; SHORT HAIRPIN RNA; SHORT HAIRPIN RNA INHIBITOR; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; C46 HIV 1 FUSION INHIBITORY PEPTIDE; C46 HIV-1 FUSION INHIBITORY PEPTIDE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELL SELECTION; CELL SURVIVAL; CONTROLLED STUDY; DNA MODIFICATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE CULTURE; NONHUMAN; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; CELL LINE; CELL MEMBRANE; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION; GENE THERAPY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MOUSE; PHYSIOLOGY; SPECIES DIFFERENCE; VIROLOGY; VIRUS ENTRY;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL MEMBRANE; CELL SURVIVAL; GENE EXPRESSION; GENE THERAPY; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MICE; RECOMBINANT FUSION PROTEINS; RNA, ANTISENSE; SPECIES SPECIFICITY; TRANSDUCTION, GENETIC; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 77957868380     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012357     Document Type: Article

References (39)

1. Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, et al. (2005) Longterm effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 366: 378-384.
2. Kozal MJ (2009) Drug-resistant human immunodefiency virus. Clin Microbiol Infect 15 Suppl 1: 69-73.
3. Patel AK, Patel KK (2006) Future implications: compliance and failure with antiretroviral treatment. J Postgrad Med 52: 197-200.
4. Montessori V, Press N, Harris M, Akagi L, Montaner JS (2004) Adverse effects of antiretroviral therapy for HIV infection. CMAJ 170: 229-238.
5. Braun SE, Johnson RP (2006) Setting the stage for bench-to-bedside movement of anti-HIV RNA inhibitors-gene therapy for AIDS in macaques. Front Biosci 11: 838-851.
6. Dropulic B, June CH (2006) Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Human Gene Therapy 17: 577-588.
7. Rossi JJ, June CH, Kohn DB (2007) Genetic therapies against HIV. Nat Biotechnol 25: 1444-1454.
8. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, et al. (2008) Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26: 808-816.
9. Egelhofer M, Brandenburg G, Martinius H, Schult-Dietrich P, Melikyan G, et al. (2004) Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol 78: 568-575.
10. Lee NS, Dohjima T, Bauer G, Li H, Li M-J, et al. (2002) Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 19: 500-505.
11. Li MJ, Kim J, Li S, Zaia J, Yee JK, et al. (2005) Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolarlocalizing TAR decoy. Mol Ther 12: 900-909.
12. Lu X, Yu Q, Binder GK, Chen Z, Slepushkina T, et al. (2004) Antisensemediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. J Virol 78: 7079-7088.
13. von Laer D, Hasselmann S, Hasselmann K (2006) Impact of gene-modified T cells on HIV infection dynamics. J Theor Biol 238: 60-77.
14. Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, et al. (2006) Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 103: 17372-17377.
15. Macpherson JL, Boyd MP, Arndt AJ, Todd AV, Fanning GC, et al. (2005) Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients. J Gene Med 7: 552-564.
16. Morgan RA, Walker R, Carter CS, Natarajan V, Tavel JA, et al. (2005) Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Ther 16: 1065-1074.
17. Woffendin C, Ranga U, Yang Z, Xu L, Nabel GJ (1996) Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virusinfected patients. Proc Natl Acad Sci U S A 93: 2889-2894.
18. van Lunzen J, Glaunsinger T, Stahmer I, von Baehr V, Baum C, et al. (2007) Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther 15: 1024-1033.
19. Amado RG, Mitsuyasu RT, Rosenblatt JD, Ngok FK, Bakker A, et al. (2004) Anti-human immunodeficiency virus hematopoietic progenitor cell-delievered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther 15: 251-262.
20. Podsakoff GM, Engel BC, Carbonaro DA, Choi C, Smogorzewska EM, et al. (2005) Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells. Mol Ther 12: 77-86.
21. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, et al. (2009) Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360: 692-698.
22. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB (1997) Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 16: 100-103.
23. Hildinger M, Dittmar MT, Schult-Dietrich P, Fehse B, Schnierle BS, et al. (2001) Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol 75: 3038-3042.
24. DiGiusto DL, Krishnan A, Li L, Li H, Li S, et al. (2010) RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Science Translational Medicine 2: 36-43.
25. Humeau L, Binder G, Lu X, Slepushkin V, Merling R, et al. (2004) Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther 9: 902-913.
26. Hermann FG, Martinius H, Egelhofer M, Giroglou T, Tonn T, et al. (2009) Protein scaffold and expression level determine antiviral activity of membraneanchored antiviral peptides. Hum Gene Ther 20: 325-336.
27. An DS, Donahue RE, Kamata M, Poon B, Metzger M, et al. (2007) Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in nonhuman primates. Proc Natl Acad Sci U S A 104: 13110-13115.
28. Swan CH, Buhler B, Steinberger P, Tschan MP, Barbas CF, 3rd, et al. (2006) Tcell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther 13: 1480-1492.
29. Estes JD, Haase AT, Schacker TW (2008) The role of collagen deposition in depleting CD4+ T cells and limiting reconstitution in HIV-1 and SIV infections through damage to the secondary lymphoid organ niche. Semin Immunol 20: 181-186.
30. Mukherjee R, Plesa G, Sherrill-Mix S, Richardson MW, Riley JL, et al. (2010) HIV sequence variation associated with env antisense adoptive T-cell therapy in the hNSG mouse model. Mol Ther 18: 803-811.
31. Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, et al. (2002) Highlevel transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13: 803-813.
32. Lu X, Humeau L, Slepushki V, Binder G, Yu Q, et al. (2004) Safe two-plasmid production for the first clinical lentivirus vector that achieves. 99% transduction in primary cells using a one-step protocol. J Gene Med 6: 963-973.
33. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15: 871-875.
34. Beyer WR, Westphal M, Ostertag W, von Laer D (2002) Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J Virol 76: 1488-1495.
35. Zahn RC, Hermann FG, Kim EY, Rett MD, Wolinsky SM, et al. (2008) Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides. Gene Ther 15: 1210-1222.
36. Braun SE, Wong FE, Connole M, Qiu G, Lee L, et al. (2005) Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells. Mol Ther 12: 1157-1167.
37. Higgins JR, Sutjipto S, Marx PA, Pedersen NC (1992) Shared antigenic epitopes of the major core proteins of human and simian immunodeficiency virus isolates. J Med Primatol 21: 265-269.
38. Johnson VA, Walker BD (1990) HIV-infected cell fusion assay. In: Walker BD and Aldovini A, eds. Techniques in HIV Research. New York: Stockton Press. pp 92-94.
39. Lohrengel S, Hermann F, Hagmann I, Oberwinkler H, Scrivano L, et al. (2005) Determinants of human immunodeficiency virus type 1 resistance to membraneanchored gp41-derived peptides. J Virol 79: 10237-10246.